Drug Eluting Stents Market by Product Type (Polymer-Based Drug Eluting Stents, Polymer-Free Drug Eluting Stents, Biodegradable Drug Eluting Stents), Application (Coronary Artery Disease, Peripheral Artery Disease), End-User Industry (Hospitals, Clinics, Ambulatory Surgical Centers), Technology (Sirolimus-Based Drug Eluting Stents, Paclitaxel-Based Drug Eluting Stents, Zotarolimus-Based Drug Eluting Stents, Everolimus-Based Drug Eluting Stents), and Regional Forecast (2024 – 2030)

As per Intent Market Research, the Drug Eluting Stents Market was valued at USD 7.4 billion in 2023 and will surpass USD 12.7 billion by 2030; growing at a CAGR of 8.0% during 2024 - 2030.

The drug eluting stents (DES) market has emerged as a critical component in the cardiovascular medical devices sector, driven by rising cases of cardiovascular diseases and advancements in stent technologies. These devices, which release medication to prevent restenosis, have revolutionized coronary and peripheral artery treatments. Increasing healthcare expenditure, coupled with technological innovations, is fostering rapid growth in this market.

Polymer-Based Stents Segment is Largest Owing to Widespread Adoption

Polymer-based drug eluting stents dominate the market, accounting for the largest share due to their extensive clinical applications and proven efficacy. These stents utilize a polymer coating to deliver drugs like sirolimus and paclitaxel, ensuring controlled drug release over time. Their ability to significantly reduce restenosis rates makes them the preferred choice among healthcare professionals.

Ongoing research and development in polymer technologies are enhancing the biocompatibility and drug delivery efficiency of these stents. Their widespread use in coronary artery disease treatments underscores their dominance in the global market. The high adoption rate of polymer-based stents is also supported by their inclusion in various clinical guidelines for interventional cardiology.

Biodegradable Stents Segment is Fastest Growing Due to Long-Term Benefits

Biodegradable drug eluting stents represent the fastest-growing segment, driven by their potential to minimize long-term complications. These stents dissolve or degrade naturally after fulfilling their purpose, eliminating the need for additional surgical removal.

The increasing preference for biodegradable stents is bolstered by their ability to reduce late-stage restenosis and adverse events associated with permanent implants. Healthcare providers are increasingly adopting these stents for their ability to promote vascular healing, making them a vital growth driver in the DES market.

Coronary Artery Disease Segment is Largest Owing to High Prevalence Rates

The coronary artery disease (CAD) segment holds the largest market share, primarily due to the high prevalence of CAD globally. With cardiovascular diseases being a leading cause of mortality, the demand for effective treatment solutions such as DES is on the rise.

DES have become a cornerstone in managing CAD by preventing restenosis following angioplasty procedures. The segment's dominance is further reinforced by the growing number of percutaneous coronary interventions (PCI) performed worldwide, supported by an aging population and increased risk factors like diabetes and obesity.

Peripheral Artery Disease Segment is Fastest Growing Due to Rising Awareness

Peripheral artery disease (PAD) is the fastest-growing application segment as awareness about the condition and its treatment options increases. Drug eluting stents for PAD are gaining traction for their role in maintaining arterial patency and reducing the need for repeat procedures.

This growth is also fueled by the development of specialized stents designed for challenging peripheral anatomies. As the incidence of PAD rises due to aging populations and lifestyle changes, the demand for effective interventions like DES is expected to accelerate.

Hospitals Segment is Largest Owing to Advanced Infrastructure

Hospitals account for the largest end-user segment in the DES market, thanks to their advanced infrastructure and availability of skilled healthcare professionals. Most complex interventional procedures, including those requiring DES, are performed in hospital settings equipped with state-of-the-art technology.

The increasing prevalence of cardiovascular diseases has led to higher hospitalization rates for diagnostic and therapeutic procedures, further solidifying hospitals as the dominant end-user segment. The availability of insurance coverage for hospital-based treatments also plays a crucial role in driving this segment's growth.

Ambulatory Surgical Centers Segment is Fastest Growing Due to Cost-Effectiveness

Ambulatory surgical centers (ASCs) represent the fastest-growing end-user segment, driven by their cost-effective and efficient care delivery model. These centers are increasingly equipped to perform minimally invasive procedures, including those involving DES, making them a preferred choice for patients and providers alike.

The reduced recovery times and lower costs associated with ASCs are attracting a growing number of cardiovascular patients, particularly in developed markets. The trend toward outpatient care is further accelerating the adoption of DES in these settings.

Sirolimus-Based Stents Segment is Largest Due to Proven Efficacy

Sirolimus-based drug eluting stents lead the technology segment due to their long-standing track record of safety and efficacy. These stents release sirolimus, an immunosuppressive agent that inhibits smooth muscle cell proliferation, effectively reducing restenosis rates.

Their widespread use in both coronary and peripheral artery interventions underscores their dominance in the DES market. Continuous innovations in sirolimus delivery mechanisms are enhancing their therapeutic outcomes, further driving their adoption.

Zotarolimus-Based Stents Segment is Fastest Growing Due to Technological Advances

Zotarolimus-based drug eluting stents are experiencing the fastest growth, thanks to ongoing advancements in drug formulation and delivery. These stents offer enhanced biocompatibility and controlled drug release profiles, addressing some of the limitations of earlier-generation stents.

The rising adoption of zotarolimus-based stents is supported by positive clinical outcomes and growing demand for next-generation technologies. As healthcare providers seek innovative solutions to improve patient outcomes, this segment is poised for significant expansion.

North America is Largest Region Due to Advanced Healthcare Infrastructure

North America dominates the global DES market, driven by advanced healthcare infrastructure, high healthcare expenditure, and a large patient pool. The region's leadership is further supported by robust reimbursement policies and the presence of major market players.

The prevalence of lifestyle-related diseases such as diabetes and obesity, which are significant risk factors for cardiovascular diseases, is also higher in North America. This has led to an increased demand for effective interventions like DES, solidifying the region's position as the largest market.

Asia-Pacific is Fastest Growing Region Due to Rising Healthcare Investments

The Asia-Pacific region is the fastest-growing market for DES, fueled by rising healthcare investments, increasing awareness about cardiovascular diseases, and improving access to advanced medical technologies. Rapid urbanization and lifestyle changes are also contributing to higher disease prevalence.

Governments in emerging economies such as China and India are investing heavily in healthcare infrastructure and initiatives to improve cardiovascular care, further accelerating market growth. The growing presence of multinational companies in the region is also driving innovation and accessibility.

Competitive Landscape

The DES market is highly competitive, with key players focusing on product innovation, strategic partnerships, and geographic expansion. Leading companies such as Abbott Laboratories, Medtronic, and Boston Scientific dominate the market with their extensive product portfolios and strong R&D capabilities.

Emerging players are also making significant strides by introducing innovative stent technologies and targeting niche markets. As the industry evolves, competition is expected to intensify, driven by advancements in materials science, drug delivery mechanisms, and manufacturing processes.

Recent Developments:

• Abbott Laboratories launched a next-generation bioresorbable drug-eluting stent in emerging markets (2024).
• Medtronic completed the acquisition of a vascular devices company to enhance its stent product portfolio (2023).
• Boston Scientific gained FDA approval for an advanced polymer-free drug-eluting stent (2024).
• MicroPort Scientific Corporation entered into a strategic partnership to develop innovative stent technologies (2023).
• Biosensors International received CE Mark approval for a new sirolimus-based drug-eluting stent for peripheral artery disease (2023).

List of Leading Companies:

• Abbott Laboratories
• Medtronic PLC
• Boston Scientific Corporation
• B. Braun Melsungen AG
• Terumo Corporation
• Biotronik SE & Co. KG
• MicroPort Scientific Corporation
• Cook Medical
• Cardinal Health, Inc.
• Biosensors International Group, Ltd.
• Koninklijke Philips N.V.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Sahajanand Medical Technologies Pvt. Ltd.
• Meril Life Sciences Pvt. Ltd.
• Translumina Therapeutics LLP

Report Scope: